scispace - formally typeset
A

Ahmedin Jemal

Researcher at American Cancer Society

Publications -  568
Citations -  492750

Ahmedin Jemal is an academic researcher from American Cancer Society. The author has contributed to research in topics: Cancer & Population. The author has an hindex of 132, co-authored 500 publications receiving 380474 citations. Previous affiliations of Ahmedin Jemal include Centers for Disease Control and Prevention & Emory University.

Papers
More filters
Journal ArticleDOI

Unemployment and cancer screening: Baseline estimates to inform health care delivery in the context of COVID-19 economic distress.

TL;DR: In this article, the authors examined associations between unemployment, health insurance, and cancer screening to inform the pandemic's potential impacts on early cancer detection, and found that unemployed adults were 4 times more likely to lack insurance than employed adults (41.4% vs 10.0%).
Journal ArticleDOI

Association between waiting time for radiotherapy initiation and disease progression among women with cervical cancer in Addis Ababa, Ethiopia.

Abstract: There is shortage of radiotherapy machines in low-income countries, including Ethiopia. Data on adverse effects of this on cancer outcomes are limited, however. Herein, we examined the extent of waiting time for radiotherapy and its association with disease progression based on a prospective cohort study of women diagnosed with stage IA-IVA cervical cancer in Addis Ababa and who were scheduled to receive radiotherapy at Tikur Anbessa Specialized Hospital, the only hospital that provides radiotherapy services in the country. Association was examined using Multivariable mixed effects logistic regression model. Among the 178 women with cervical cancer scheduled for receipt of radiotherapy and with vital status information, 16 deceased (9.0%) while waiting for radiotherapy. For the remaining 162 women who initiated radiotherapy, the median treatment waiting period was 137 days (IQR = 60-234 days), with 74.1% of women waiting for >60 days. Tumor progressed to higher stage for 44.4% of these women. Compared to those women who initiated radiotherapy ≤60 days after diagnostic confirmation, the odds of tumor progression to higher stage was three times higher in those women who initiated radiotherapy between 120-179 days (aOR =3.30, 95%CI: 1.18-9.27) and ≥180 days (aOR =3.06, 95%CI: 1.24-7.52). Waiting period for receipt of radiotherapy among women with cervical cancer is exceedingly long in Addis Ababa, and it is associated with disease progression to higher stages. These findings reinforce the need to expand radiotherapy infrastructure in order to mitigate the undue high burden of the disease in Ethiopia and other parts of Africa.
Journal ArticleDOI

Cutaneous Melanoma Incidence and Survival Among Black, Asian and Pacific Islander and White Populations in the United States

TL;DR: Five-year cause-specific survival rates were lowest for black males and females (77%), followed by API males (79%) and API females (84%).
Journal ArticleDOI

Racial and Ethnic Disparities in Interval Colorectal Cancer Incidence.

TL;DR: Improved access to CRC screening with evidence-based interventions and ensuring adequate quality are important ways to reduce interval CRC incidence, but PDRs alone may not account for all potential variations in quality, and such patient factors as follow-up on surveillance may play a role.
Journal ArticleDOI

Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: Associations with clinical variables and survival.

TL;DR: Upstaging is common and is associated with decreased 5-year survival in BC patients treated with RC, and these data can be used in pre-operative risk stratification, treatment decision making and comparison with studies of non-operative management.